Improvement of lower urinary tract symptoms and incidence of retrograde ejaculation when 2.5mg or 5mg of Terazosin is administered to patients with benign prostatic hyperplasia

Improvement of lower urinary tract symptoms and incidence of retrograde ejaculation when 2.5mg or 5mg of Terazosin is administered to patients with benign prostatic hyperplaisa

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0005531

Enrollment

142

Registered

2020-10-26

Start date

2020-11-30

Completion date

Unknown

Last updated

2020-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : A: Terazosin 2.5mg QD group B: Terazosin 5mg QD group

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1) Adult male over 19 years old 2) Those with an IPSS total score of 8 or more 3) Those with a maximum urine velocity (Qmax) of less than 10mL/s 4) Those who agreed to participate in this study by handwriting

Exclusion criteria

Exclusion criteria: 1) Those who are hypersensitive to a-blocker drugs 2) Those with bladder neck stenosis or urinary tract stenosis 3) Those with renal dysfunction (serum creatine concentration>2.0mg/dL) 4) Those with severe liver disorder or medical history 5) Those with severe cardiovascular disease 6) Those with severe low blood pressure 7) Others who are inadequate to participate in this research as the research director judges

Design outcomes

Primary

Measure	Time frame
International Prostate Symptom Score	—

Secondary

Measure	Time frame
Number of patients who experience retrograde ejaculation	—

Countries

Korea, Republic of

Contacts

Public ContactJa Yoon Koo

Pusan National University Hospital

Outcome results